$GCTK
GlucoTrack Inc

2023 Q2 Form 10-Q Financial Statement

#000149315223016706 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $552.0K $642.0K $633.0K
YoY Change -15.6% 1.42% 7.84%
% of Gross Profit
Research & Development $627.0K $642.0K $460.0K
YoY Change 33.69% 39.57% 48.87%
% of Gross Profit
Depreciation & Amortization $3.000K $4.000K $9.000K
YoY Change -40.0% -55.56% -25.0%
% of Gross Profit
Operating Expenses $1.179M $1.284M $1.093M
YoY Change 4.99% 17.47% 21.99%
Operating Profit -$1.179M -$1.284M -$1.093M
YoY Change 4.99% 17.47%
Interest Expense $3.000K -$2.000K $0.00
YoY Change -175.0% -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.176M -$1.286M -$1.093M
YoY Change 4.35% 17.66% 20.91%
Income Tax
% Of Pretax Income
Net Earnings -$1.176M -$1.286M -$1.093M
YoY Change 4.35% 17.66% 20.91%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.08 -$0.07
Diluted Earnings Per Share -$0.09 -$0.08 -$70.69K
COMMON SHARES
Basic Shares Outstanding 20.89M shares 15.50M shares 15.46M shares
Diluted Shares Outstanding 21.56M shares 15.50M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.774M $1.003M $4.789M
YoY Change 127.66% -79.06% -46.11%
Cash & Equivalents $8.774M $1.003M $4.789M
Short-Term Investments
Other Short-Term Assets $171.0K $203.0K $442.0K
YoY Change -53.78% -54.07% 882.22%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.945M $1.206M $5.231M
YoY Change 111.77% -76.95% -43.63%
LONG-TERM ASSETS
Property, Plant & Equipment $27.00K $35.00K $78.00K
YoY Change -44.9% -55.13% -72.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $50.00K
YoY Change -77.27% -80.0% -24.24%
Total Long-Term Assets $37.00K $45.00K $128.0K
YoY Change -60.22% -64.84% -63.22%
TOTAL ASSETS
Total Short-Term Assets $8.945M $1.206M $5.231M
Total Long-Term Assets $37.00K $45.00K $128.0K
Total Assets $8.982M $1.251M $5.359M
YoY Change 108.06% -76.66% -44.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $832.0K $652.0K $590.0K
YoY Change 34.85% 10.51% -14.99%
Accrued Expenses $12.00K
YoY Change -89.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.050M $1.047M $916.0K
YoY Change 12.3% 14.3% -26.6%
LONG-TERM LIABILITIES
Long-Term Debt $189.0K $193.0K $206.0K
YoY Change -1.56% -6.31% 7.29%
Other Long-Term Liabilities $189.0K $193.0K $6.000K
YoY Change 3116.67% -84.62%
Total Long-Term Liabilities $189.0K $193.0K $212.0K
YoY Change -1.56% -8.96% -8.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.050M $1.047M $916.0K
Total Long-Term Liabilities $189.0K $193.0K $212.0K
Total Liabilities $1.239M $1.240M $1.128M
YoY Change 9.94% 9.93% -23.73%
SHAREHOLDERS EQUITY
Retained Earnings -$105.2M -$103.2M
YoY Change 5.55%
Common Stock $112.9M $103.2M
YoY Change 9.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.743M $11.00K $4.231M
YoY Change
Total Liabilities & Shareholders Equity $8.982M $1.251M $5.359M
YoY Change 108.06% -76.66% -44.34%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.176M -$1.286M -$1.093M
YoY Change 4.35% 17.66% 20.91%
Depreciation, Depletion And Amortization $3.000K $4.000K $9.000K
YoY Change -40.0% -55.56% -25.0%
Cash From Operating Activities -$954.0K -$1.313M -$1.265M
YoY Change 4.15% 3.79% 35.58%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.730M
YoY Change
NET CHANGE
Cash From Operating Activities -954.0K -$1.313M -1.265M
Cash From Investing Activities 0.000
Cash From Financing Activities 8.730M
Net Change In Cash 7.776M -$1.318M -1.265M
YoY Change -945.22% 4.19% 35.58%
FREE CASH FLOW
Cash From Operating Activities -$954.0K -$1.313M -$1.265M
Capital Expenditures $0.00
Free Cash Flow -$954.0K -$1.313M
YoY Change 4.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
193000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
195000 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
193000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
195000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1240000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1208000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15503632 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15503632 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15500730 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15500730 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
15000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
15000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15503632 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15503632 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15500730 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15500730 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
15000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
15000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
103156000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
103095000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
17000 usd
CY2023Q1 GCTK Receipts On Account Of Shares
ReceiptsOnAccountOfShares
5000 usd
CY2022Q4 GCTK Receipts On Account Of Shares
ReceiptsOnAccountOfShares
4000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103187000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101901000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1230000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1251000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2438000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
642000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
460000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
642000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
633000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1284000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
1093000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1284000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1093000 usd
CY2023Q1 GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
-2000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1286000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1093000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1281000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1086000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15503632 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15461757 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5155000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1093000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
151000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
11000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4231000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1230000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1286000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
57000 usd
CY2023Q1 GCTK Stock Issued During Period Value Restricted Stock Award Net
StockIssuedDuringPeriodValueRestrictedStockAwardNet
5000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1286000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1093000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
4000 usd
CY2022Q1 us-gaap Depreciation
Depreciation
9000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
57000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
151000 usd
CY2023Q1 GCTK Issuance Of Restricted Shares As Compensation To Board Of Directors
IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
5000 usd
CY2022Q1 GCTK Issuance Of Restricted Shares As Compensation To Board Of Directors
IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
11000 usd
CY2023Q1 GCTK Linkage Difference On Principal Of Loans From Stockholders
LinkageDifferenceOnPrincipalOfLoansFromStockholders
2000 usd
CY2022Q1 GCTK Linkage Difference On Principal Of Loans From Stockholders
LinkageDifferenceOnPrincipalOfLoansFromStockholders
2000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
137000 usd
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
400000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-13000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-35000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
55000 usd
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
90000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1313000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1265000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-5000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-9000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1318000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1274000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2331000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6113000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1013000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4839000 usd
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07070
CY2023Q1 dei City Area Code
CityAreaCode
201
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001506983
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Other Liability Noncurrent Related Party Type Extensible Enumeration
OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration
http://glucotrack.com/20230331#StockholderMember
CY2022Q4 us-gaap Other Liability Noncurrent Related Party Type Extensible Enumeration
OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration
http://glucotrack.com/20230331#StockholderMember
CY2022Q1 GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-41141
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
GLUCOTRACK, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0668934
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
301 Route 17 North
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Rutherford
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
842-7715
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
GCTK
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20892193 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1003000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2312000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
203000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
67000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1206000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2379000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
35000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40000 usd
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
19000 usd
CY2023Q1 us-gaap Assets
Assets
1251000 usd
CY2022Q4 us-gaap Assets
Assets
2438000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
652000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
672000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
395000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
341000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1047000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1013000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103187000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1003000 usd
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
8730000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_zjx0iBsGktkk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"/> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zWZdfRNZ3CKe">Use of estimates in the preparation of financial statements</span></b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated interim condensed financial statements, the most significant estimates and assumptions relate to the going concern assumptions.</span></td></tr> </table>
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2500000 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
gctk-20230331_pre.xml Edgar Link unprocessable
0001493152-23-016706-index-headers.html Edgar Link pending
0001493152-23-016706-index.html Edgar Link pending
0001493152-23-016706.txt Edgar Link pending
0001493152-23-016706-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
gctk-20230331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gctk-20230331_def.xml Edgar Link unprocessable
gctk-20230331_cal.xml Edgar Link unprocessable
gctk-20230331_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed